Allergies are debilitating and sometimes deadly. More than a fifth of the world’s population is affected to some degree. Despite this, they are a relatively neglected area of research. That may, however, finally be changing.
Xolair, a drug originally approved in 2003 for severe asthma, recently won approval as the first FDA-approved medication to reduce allergic reactions to multiple food types. The drug, which is jointly marketed in the US by Novartis and Roche, allowed more than two-thirds of trialists who were allergic to peanuts to tolerate the equivalent of two and a half peanuts after about four months of treatment.
您已阅读23%（712字），剩余77%（2323字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。